89bio, Inc.
Clinical trials sponsored by 89bio, Inc., explained in plain language.
-
New drug aims to tame dangerous fat levels in blood
Disease control CompletedThis study tested a drug called pegozafermin in 369 adults with severe hypertriglyceridemia, a condition where blood fat levels are dangerously high. Participants received either the drug or a placebo for 26 weeks. The main goal was to see if the drug could safely lower triglycer…
Phase: PHASE3 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise for reversing liver damage in NASH patients
Disease control CompletedThis study tested a new drug called BIO89-100 (Pegozafermin) in 222 adults with NASH, a serious fatty liver disease with liver scarring. Participants received weekly injections of the drug or a placebo for about 6 months. The goal was to see if the drug could reduce liver inflamm…
Phase: PHASE2 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC